SCHEMBL926877

SCHEMBL926877

Nc1cccc2ocnc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPT P10636 2/20 0.36
HIF1A Q16665 1/20 0.36
PARP1 P09874 2/20 0.35
PIN1 Q13526 2/20 0.35
CYP3A4 P08684 3/20 0.33
TDP1 Q9NUW8 3/20 0.33
DYRK1A Q13627 2/20 0.33
TSHR P16473 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
ELANE P08246 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
PIK3CA P42336 1/20 0.32
ALOX15 P16050 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1365239 0.77 NR4A2 (0.39) PIN1HTR2AHTR2CIDH1NR4A2
SCHEMBL646093 0.74 ALDH1A1 (0.42) HSD17B10KDM4EMAPTHIF1APIN1
SCHEMBL13857953 0.74 PSMD14 (0.42) PIN1HTR2AHTR2CIDH1NR4A2
SCHEMBL5687278 0.74 BACE1 (0.35) PIN1IDH1NR4A2DHODHEPHB4
SCHEMBL288687 0.74 PIN1 (0.35) PIN1IDH1NR4A2DHODHEPHB4
SCHEMBL2005830 0.74 PIN1 (0.40) PIN1DYRK1AALDH1A1ELANESMN1; SMN2
SCHEMBL17177020 0.74 PIN1 (0.35) PIN1IDH1NR4A2DHODHEPHB4
SCHEMBL3356073 0.74 NR4A2 (0.38) KDM4EMAPTPARP1PIN1ALDH1A1
SCHEMBL288688 0.74 ELANE (0.43) KDM4EPARP1PIN1TSHRALDH1A1
SCHEMBL1881059 0.74 PIN1 (0.40) MAPTPARP1PIN1TDP1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118359961-A Water-based ink capable of rapidly detecting trace migration and detection method thereof 上海高邦印刷材料有限公司 2024-07-19 CN claimed
CN-110156712-A It is a kind of to utilize aromatic nitration by-product synthesis benzoxazoles class compound and application 邵玉田 2019-08-23 CN claimed
CN-110105568-A A method of utilizing aromatic nitration by-product production PBI functional material 邵玉田 2019-08-09 CN claimed
EP-4709384-A2 COMBINATION THERAPY FOR TREATMENT OF CANCER PMV Pharmaceuticals, Inc. (US) 2026-03-18 EP disclosed
US-20250326760-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-10-23 US disclosed
EP-4605392-A1 METHODS FOR TREATING CANCER Antares Therapeutics, Inc. (US) 2025-08-27 EP disclosed
CN-116217566-B Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof 杭州和正医药有限公司 2025-05-23 CN disclosed
US-20250034135-A1 ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF Hangzhou Healzen Therapeutics Co., Ltd. (CN) 2025-01-30 US disclosed
CN-119156230-A Ligand-drug conjugates and uses thereof 江苏先声药业有限公司 2024-12-17 CN disclosed
US-20240400556-A1 AMIDOPYRIMIDONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2024-12-05 US disclosed
US-20240400531-A1 HERBICIDAL MALONAMIDES CONTAINING A CONDENSED RING SYSTEM BASF SE (DE) 2024-12-05 US disclosed
US-20080305051-A1 Menthane Carboxamide Derivatives Having Cooling Properties GIVAUDAN S.A. (CH) 2008-12-11 US disclosed
CN-101137660-A Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives as antidiabetic compounds HOFFMANN LA ROCHE (CH) 2008-03-05 CN disclosed
EP-1853565-A1 MENTHANE CARBOXAMIDE DERIVATIVES HAVING COOLING PROPERTIES Givaudan SA (CH) 2007-11-14 EP disclosed
WO-2006092074-A1 MENTHANE CARBOXAMIDE DERIVATIVES HAVING COOLING PROPERTIES GIVAUDAN SA (CH) 2006-09-08 WO disclosed
EP-1509515-A4 SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA INC (US) 2006-07-05 EP disclosed
US-20060104998-A1 Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2006-05-18 US disclosed
EP-1509515-A2 SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2005-03-02 EP disclosed
WO-2003097806-A2 SUBSTITUTED 4-ARYL-4H-PYRROLO[2,3-H]CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2003-11-27 WO disclosed
WO-2003053960-A2 QUINLINE DERIVATES AND THEIR USE AS MEK INHIBITORS ASTRAZENECA AB (SE) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060104998-A1 Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP3, CASP4, CASP2 HSD17B10 799/4885KDM4E 486/4885MAPT 4700/4885
US-20240400531-A1 HERBICIDAL MALONAMIDES CONTAINING A CONDENSED RING SYSTEM DDT, ME3, ME1 HSD17B10 449/4885KDM4E 244/4885MAPT 1816/4885
US-20250034135-A1 ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF BCL2, BAX, BCL2L1 HSD17B10 3375/4885KDM4E 3877/4885MAPT 2800/4885
US-20250326760-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 HSD17B10 2692/4885KDM4E 391/4885MAPT 1236/4885
US-20080305051-A1 Menthane Carboxamide Derivatives Having Cooling Properties MDH2, ME2, H1-0 HSD17B10 687/4885KDM4E 10/4885MAPT 1003/4885
US-20240400556-A1 AMIDOPYRIMIDONE DERIVATIVES F12, XDH, CYP3A43 HSD17B10 2286/4885KDM4E 2655/4885MAPT 4070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.